From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)

From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC)

Following the results of the CROWN phase III trial, the third-generation macrocyclic ALK inhibitor lorlatinib has been introduced as a salvage option after the failure of a first-line TKI in ALK-rearranged NSCLC, while its precise role in the therapeutic algorithm of ROS1 positive disease is still t...

Full description

Bibliographic Details
Main Authors: Laura Fabbri, Alessandro Di Federico, Martina Astore, Virginia Marchiori, Agnese Rejtano, Renata Seminerio, Francesco Gelsomino, Andrea De Giglio
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Diagnostics
Subjects:
lorlatinib
tyrosine kinase inhibitors
anaplastic large cell lymphoma
ROS proto-oncogene 1 (ROS1)
non-small cell lung cancer
central nervous system
Online Access:https://www.mdpi.com/2075-4418/14/1/48

Internet

https://www.mdpi.com/2075-4418/14/1/48

Similar Items